Form 4: Agios Pharmaceuticals' Chief Legal Officer Sells Shares Under 10b5-1 Plan

James William Burns, Chief Legal Officer of Agios Pharmaceuticals, sold shares of common stock on November 7, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• James William Burns, the Chief Legal Officer of Agios Pharmaceuticals, sold shares of the company's common stock on November 7, 2024.
• The sales were executed under a Rule 10b5-1 trading plan.
• A total of 13,411 shares were sold at a weighted average price of $52, with individual prices ranging from $51.33 to $52.32.
• An additional 8,341 shares were sold at a weighted average price of $52.56, with individual prices ranging from $52.33 to $52.88.
• Following these transactions, Burns directly owns 15,700 shares of Agios Pharmaceuticals' common stock, which includes 3,091 shares purchased through the company's employee stock purchase plan.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing related to stock sales by an officer. It doesn't inherently convey positive or negative sentiment, as it's a routine disclosure.

Industry Context

Sales by company insiders are a common occurrence and are often related to personal financial planning. The use of a 10b5-1 trading plan allows insiders to sell shares at predetermined times and prices, avoiding concerns about insider trading.

Stakeholder Impact

• The stock sales by a company officer could have a minor negative impact on shareholder sentiment, but the use of a 10b5-1 plan mitigates concerns about insider trading.

Key Dates